Contrasting Arvinas (NASDAQ:ARVN) and NeuroSense Therapeutics (NASDAQ:NRSN)

Arvinas (NASDAQ:ARVN) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Arvinas and NeuroSense Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
NeuroSense Therapeutics	N/A	N/A	N/A

Volatility and Risk

Arvinas has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.

Earnings and Valuation

This table compares Arvinas and NeuroSense Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60 million	2.23	-$80.80 million	($3.32)	-2.73
NeuroSense Therapeutics	N/A	N/A	-$11.12 million	($0.54)	-1.53

NeuroSense Therapeutics has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Arvinas and NeuroSense Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	3	3	8	0	2.36
NeuroSense Therapeutics	1	1	2	1	2.60

Arvinas currently has a consensus target price of $14.69, suggesting a potential upside of 61.81%. NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 928.31%. Given NeuroSense Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Arvinas.

Institutional & Insider Ownership

95.2% of Arvinas shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 7.3% of Arvinas shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

NeuroSense Therapeutics beats Arvinas on 10 of the 14 factors compared between the two stocks.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.